IL-FOURKITES
Leading real-time supply chain visibility company FourKites today announced it will bring its network of end-to-end, real-time supply chain data to Spotos’ European customers. German-based Spotos offers a digital freight forwarding platform that gives shippers access to a wide network of carriers across Europe.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230306005078/en/
FourKites and Spotos Join Forces to Bring Real-time Supply Chain Visibility to European Shippers (Graphic: Business Wire)
The partnership can give Spotos’ customers up-to-the-minute predictive estimated times of arrival (ETAs) and real-time status updates for their shipments at anytime, anywhere in Europe, whether in transit or at rest. With these advanced insights provided by FourKites, Spotos’ customers can reduce dwell and detention costs while optimising their network as shippers look to manage their costs better.
“Our mission is to revolutionise traditional freight exchange by enabling the best transparency, simplicity and accessibility for small and medium shippers,” said Šarūnas Stanislovėnas, founder and CEO of Spotos. “Now, thanks to FourKites' predictive insights, we will be able to provide our customers with ETAs that are more accurate and detailed than other available technologies could reliably deliver."
Spotos will also leverage FourKites’ carrier visibility platform, NIC-Place. This will give its customers access to granular data, including temperature tracking data for high-value transports, such as pharmaceuticals, fresh and frozen products, and electronic equipment throughout all parts of their fleet. With its proprietary Data Control Center (DCC), FourKites’ NIC-Place solution can provide a flexible and secure way for carriers to share supply chain data with customers, while giving them complete control of their business, their network and their data.
Based in Berlin, Spotos’ fully automated spot freight forwarding platform assures the highest-level service experience for small and medium-sized (SMB) shippers, regardless of their order volume or frequency. FourKites’ offering — powered by cutting-edge artificial intelligence and machine learning — will integrate with Spotos’ platform to extend visibility beyond transportation into yards, warehouses, stores and more.
Visibility across the entire supply chain network is crucial for SMB customers shipping high-value goods. By leveraging FourKites’ market-leading data network, Spotos’ customers can dynamically react to changes in plans and make more informed decisions in real time. In addition, FourKites will fuel insights that drive smarter operational planning and uncover new opportunities for operational efficiencies and cost savings.
“We’re delighted to team up with Spotos to ensure their customers can seamlessly track their freight in one unified platform,” said Marc Boileau, FourKites’ Senior Vice President of Sales, Network & Operations EMEA. “With FourKites, Spotos gets the most advanced tracking features for true end-to-end visibility, giving them a single pane of glass solution and the industry’s most accurate predictive ETAs for every shipment.”
“We’re excited about our partnership with FourKites,” continued Stanislovėnas. “FourKites has proven itself to be a true partner that has our best interests at heart and is always striving to do what’s right for our business and our customers.”
About FourKites
Leading supply chain visibility platform FourKites® extends visibility beyond transportation into yards, warehouses, stores and beyond. Tracking more than 3 million shipments daily across road, rail, ocean, air, parcel and last mile, and reaching over 200 countries and territories, FourKites combines real-time data and powerful machine learning to help companies digitise their end-to-end supply chains. More than 1,200 of the world’s most recognised brands — including 9 of the top-10 CPG and 18 of the top-20 food and beverage companies — trust FourKites to transform their business and create more agile, efficient and sustainable supply chains. To learn more, visit https://www.fourkites.com/.
About Spotos
Spotos revolutionised the old-school logistics industry, combining it with cutting-edge innovation, customer-oriented design, and a futuristic vision. It offers shippers access to a wide network of carriers across the EU region. The platform powertrain includes data science, artificial intelligence and machine learning.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230306005078/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
